• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
US CNS Disorders Drug Pipeline Insight 2014 - Product Image Special Offer Sale Banner

US CNS Disorders Drug Pipeline Insight 2014

  • ID: 2931017
  • August 2014
  • Region: United States
  • 1700 Pages
  • PNS Pharma
Special Offer Banner
20%
OFF
Offer ends 10th Jan 2015

FEATURED COMPANIES

  • Alkermes
  • AstraZeneca
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Novartis
  • Roche
  • MORE

The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer’s markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

New technology including advancements READ MORE >

FEATURED COMPANIES

  • Alkermes
  • AstraZeneca
  • Bristol-Myers Squibb
  • GlaxoSmithKline
  • Novartis
  • Roche
  • MORE

1. Introduction to Central Nervous System (CNS) Disorder

2. US Central Nervous System (CNS) Disorder Market Overview
2.1 Market Overview
2.2 Clinical Pipeline Insight

3. US Central Nervous System (CNS) Disorder Incidence by Disease
3.1 Alzheimer's Disease
3.2 Multiple Sclerosis
3.3 Epilepsy
3.4 Parkinson Disease
3.5 Migraine
3.6 Huntington's disease
3.7 Schizophrenia
3.8 Anxiety
3.9 Insomnia
3.10 Bipolar Disorder
3.11 ADHD

4. US Central Nervous System (CNS) Disorder Market Dynamics
4.1 Favorable Market Parameters
4.2 Market Challenges
4.3 Future Growth Opportunity

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company
5.1 Clinical Pipeline Insight by Phase & Company
5.2 Marketed Drugs Clinical Profile

6. US Alzheimer's Disease Drug Pipeline by Phase & Company
6.1 Clinical Pipeline Insight by Phase & Company
6.2 Marketed Drug Clinical Profile

7. US Multiple Sclerosis Drug Pipeline by Phase & Company
7.1 Clinical Pipeline Insight by Phase & Company
7.2 Marketed Drug Clinical Profile

8. US Parkinson's Disease Drug Pipeline by Phase & Company
8.1 Clinical Pipeline Insight by Phase & Company
8.2 Marketed Drug Clinical Profile

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company
9.1 Clinical Pipeline Insight by Phase & Company
9.2 Marketed Drug Clinical Profile

10. US Epilepsy Drug Pipeline by Phase & Company
10.1 Clinical Pipeline Insight by Phase & Company
10.2 Marketed Drug Clinical Profile

11. US Migraine Drug Pipeline by Phase & Company
11.1 Clinical Pipeline Insight by Phase & Company
11.2 Marketed Drug Clinical Profile

12. US Huntington's Disease Drug Pipeline by Phase & Company
12.1 Clinical Pipeline Insight by Phase & Company
12.2 Marketed Drug Clinical Profile

13. US Neuropathic Pain Clinical Pipeline by Phase & Company
13.1 Clinical Pipeline Insight by Phase & Company
13.2 Marketed Drug Clinical Profile

14. US Schizophrenia Clinical Trial Insight by Phase & Company
14.1 Clinical Pipeline Insight by Phase & Company
14.2 Marketed Drug Clinical Profile

15. US Sleep Disorders Drug Pipeline by Phase & Company
15.1 Clinical Pipeline Insight by Phase & Company
15.2 Marketed Drug Clinical Profile

16. Competitive Landscape
16.1 Alkermes
16.2 Allergan
16.3 AstraZeneca
16.4 Biogen Idec
16.5 Bristol-Myers Squibb
16.6 Eli Lilly
16.7 GlaxoSmithKline
16.8 Merck
16.9 Novartis
16.10 Pfizer
16.11 Roche
16.12 Sanofi
16.13 Sunovion Pharmaceuticals
16.14 Teva Pharmaceutical

List Of Figures:

Figure 2-1: US - CNS Disorders Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-2: US - CNS Disorders Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-3: US - CNS Disorder Drugs Clinical Pipeline by Disease (%), 2014
Figure 2-4: US - CNS Disorder Drugs Clinical Pipeline by Disease (Number), 2014
Figure 2-5: US - CNS Disorder Drugs in Research Phase by Disease (%), 2014
Figure 2-6: US - CNS Disorder Drugs in Research Phase by Disease (Number), 2014
Figure 2-7: US - CNS Disorder Drugs in Preclinical Phase by Disease (%), 2014
Figure 2-8: US - CNS Disorder Drugs in Preclinical Phase by Disease (Number), 2014
Figure 2-9: US - CNS Disorder Drugs in Clinical Phase by Disease (%), 2014
Figure 2-10: US - CNS Disorder Drugs in Clinical Phase by Disease (Number), 2014
Figure 2-11: US - CNS Disorder Drugs in Phase-0 by Disease (%), 2014
Figure 2-12: US - CNS Disorder Drugs in Phase-0 by Disease (Number), 2014
Figure 2-13: US - CNS Disorder Drugs in Phase-I by Disease (%), 2014
Figure 2-14: US - CNS Disorder Drugs in Phase-I by Disease (Number), 2014
Figure 2-15: US - CNS Disorder Drugs in Phase-I/II by Disease (%), 2014
Figure 2-16: US - CNS Disorder Drugs in Phase-I/II by Disease (Number), 2014
Figure 2-17: US - CNS Disorder Drugs in Phase-II by Disease (%), 2014
Figure 2-18: US - CNS Disorder Drugs in Phase-II by Disease (Number), 2014
Figure 2-19: US - CNS Disorder Drugs in Phase-II/III by Disease (%), 2014
Figure 2-20: US - CNS Disorder Drugs in Phase-II/III by Disease (Number), 2014
Figure 2-21: US - CNS Disorder Drugs in Phase-III by Disease (%), 2014
Figure 2-22: US - CNS Disorder Drugs in Phase-III by Disease (Number), 2014
Figure 2-23: US - CNS Disorder Drugs in Preregistration Phase by Disease (%), 2014
Figure 2-24: US - CNS Disorder Drugs in Preregistration Phase by Disease (Number), 2014
Figure 2-25: US - CNS Disorder Drugs in Registration Phase by Disease (%), 2014
Figure 2-26: US - CNS Disorder Drugs in Registration Phase by Disease (Number), 2014
Figure 2-27: US - Marketed CNS Disorder Drugs by Disease (%), 2014
Figure 2-28: US - Marketed CNS Disorder Drugs by Disease (Number), 2014
Figure 2-29: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-30: US - Alzheimer's Disease Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-31: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-32: US - Multiple Sclerosis Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-33: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-34: US - Parkinson's Disease Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-35: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-36: US - Neurodegenerative Disorders Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-37: US - Epilepsy Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-38: US - Epilepsy Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-39: US - Migraine Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-40: US - Migraine Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-41: US - Huntington's Disease Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-42: US - Huntington's Disease Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-43: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-44: US - Neuropathic Pain Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-45: US - Schizophrenia Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-46: US - Schizophrenia Drugs Clinical Pipeline by Phase (Number), 2014
Figure 2-47: US - Sleep Disorders Drugs Clinical Pipeline by Phase (%), 2014
Figure 2-48: US - Sleep Disorders Drugs Clinical Pipeline by Phase (Number), 2014
Figure 3-1: US - Alzheimer’s Disease Incidence (Million), 2013-2020
Figure 3-2: US - Multiple Sclerosis Incidence (‘000), 2013-2020
Figure 3-3: US - Epilepsy Incidence (Million), 2013-2020
Figure 3-4: US - Parkinson’s Disease Incidence (Million), 2013-2020
Figure 3-5: US - Migraine Incidence (Million), 2013-2020
Figure 3-6: US - Huntington’s Disease Incidence (‘000), 2013-2020
Figure 3-7: US - Schizophrenia Disease Incidence (Million), 2013-2020
Figure 3-8: US - Anxiety Disorder Incidence (Million), 2013-2020
Figure 3-9: US - Insomnia Incidence (Million), 2013-2020
Figure 3-10: US - Bipolar Disorder Incidence (Million), 2013-2020
Figure 3-11: US - ADHD Incidence (Million), 2013-2020

- Alkermes
- Allergan
- AstraZeneca
- Biogen Idec
- Bristol-Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Roche
- Sanofi
- Sunovion Pharmaceuticals
- Teva Pharmaceutical

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos